Lorenza Rimassa
Academic History
Lorenza Rimassa, MD, is Associate Professor of Oncology at Humanitas University and Head of the Hepatopancreatobiliary Oncology and Hematology Unit at IRCCS Humanitas Research Hospital, Milan, Italy. She actively contributes to medical education as Deputy Director of the Residency Program in Medical Oncology and plays a key role in the oversight of academic and doctoral training at Humanitas University. Dr Rimassa earned her medical degree and completed her residency in Medical Oncology at the University of Milan, Milan, Italy.
She holds leadership positions in several national and international organizations, including her role as Treasurer and Executive Committee member of the International Liver Cancer Association (ILCA). She chairs the EORTC Hepatopancreatobiliary and Neuroendocrine Tumors Task Force and co-chairs the Technical Commission on liver and biliary tract cancers for the Lombardy Oncology Network. She also co-chairs the hepatobiliary task force of the U.S. National Cancer Institute and contributes to key guideline efforts, including the ESMO Guidelines for Biliary Tract Cancer (2022) and Italy’s National Guideline System (SNLG). She is also a member of European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the European Association for the Study of the Liver (EASL), the International Liver Cancer Association (ILCA), the Italian Association of Medical Oncology (AIOM), and other collaborative networks advancing hepatobiliary cancer care.
Speaking on translational drug development and biomarkers in GI cancers
Dr Rimassa specializes in the clinical and translational development of systemic therapies for gastrointestinal cancers, particularly hepatocellular carcinoma (HCC) and cholangiocarcinoma. Her work focuses on early- to late-phase clinical trials of immunotherapies, targeted agents, and biomarker-driven treatments. She is also involved in translational research to identify and validate prognostic and predictive biomarkers and to integrate molecular profiling into clinical decision-making. Beyond research, she contributes to national and international guideline development aimed at standardizing care for hepatobiliary cancers.
